Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial

British Journal of Dermatology

Volumn 153, Issue 6, 2005, Pages 1192-1199

  Krueger, Gerald G ^a   Langley, R G ^b   Finlay, A Y ^c   Griffiths, C E M ^d   Woolley, J M ^e   Lalla, D ^e   Jahreis, A ^e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e AMGEN INC   (United States)

Author keywords

Etanercept; Patient reported outcomes; Psoriasis; Quality of life; Randomized controlled trial; Tumour necrosis factor

Indexed keywords

ETANERCEPT; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; PATIENT INFORMATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SHORT FORM 36; TREATMENT OUTCOME;

ADULT; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PRURITUS; PSORIASIS; PSYCHOMETRICS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 28844490562     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06948.x     Document Type: Article

References (17)

1. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CEM. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137:755-60.
2. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139:846-50.
3. Lundberg L, Johannesson M, Silverdahl M et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol (Stockh) 2000; 80:430-4.
4. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14:485-96.
5. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132:236-44.
6. Krueger GM, Koo JM, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-4.
7. Kirby B, Richards HL, Woo P et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45:72-6.
8. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304-12.
9. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
10. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16.
11. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9:169-80.
12. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147 (Suppl. 62): 50 (Abstract).
13. Kimball A, Krueger G, Woolley JM. Minimal important differences for the Dermatology Life Quality Index (DLQI) in psoriasis patients. Poster presented at American Academy of Dermatology Summer Academy Meeting, New York, 2004.
14. Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005; in press.
15. Ware JE, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, RI: Quality Metric Inc., 2000.
16. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150:317-26.
17. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290:3073-80.